We were delighted to talk to Masanori Terashima about the advantages of robot-assisted gastrectomy for clinical stage T1-2N0-2 gastric cancer patients (Clinical Trial Identifier: UMIN000039825).
The abstract ‘Randomized controlled phase III trial to investigate superiority of robot-assisted gastrectomy over laparoscopic gastrectomy for clinical stage T1-2N0-2 gastric cancer patients: Japan Clinical Oncology Group study JCOG1907 (MONA LISA study)’ (ABSTRACT NUMBER: TPS254) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.
- Could you give us a brief overview of the postoperative complications that may occur after surgery in gastric cancer, and their prognostic significance? (0:14)
- What are the advantages and limitations of laparoscopic gastrectomy compared with open gastrectomy? (0:55)
- Could you tell us a little about robot-assisted gastrectomy and its clinical development to date? (2:02)
- What are the aims and design of the JCOG1907 study? (3:05)
- What does the future hold for robot-assisted surgical procedures in oncology? (3:52)
Disclosures: Masanori Terashima has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ASCO GI 2021 (Virtual).
Share this Video
Related Videos In Gastrointestinal Oncology
Jared Weiss, ESMO 2021: The Efficacy and Safety Findings of the KRYSTAL-1 Study
touchONCOLOGY joins Dr Jared Weiss (UNC Lineburger Comprehensive Cancer Care Center, Chapel Hill, NC, USA) at ESMO 2021 to discuss KRYSTAL-1: Adagrasib (MRTX849) as Monotherapy or Combined with Cetuximab (Cetux) in Patients (Pts) With Colorectal Cancer (CRC) Harboring a KRASG12C Mutation. Questions 1. What is the rationale for targeting KRAS tumour mutations in colorectal cancer? […]
Bruno Sangro, EASL ILC 2021: Early Phase Data on Checkpoint Inhibitors in HCC
It was lovely to meet with Dr Bruno Sangro (Clínica Universidad de Navarra, Pamplona, Spain) to talk about some of the early phase data presented at EASL 2021 around immune checkpoint inhibitors in the treatment of HCC. Questions Why are patients with Child-Pugh B liver function excluded from clinical trials, and what is their prognosis? […]
Elena Garralda, ASCO 2021: Favezelimab in Metastatic Colorectal Cancer
touchONCOLOGY joins Dr Elena Garralda (Vall d’Hebron Institute of Oncology, Barcelona, Spain) at ASCO 2021 to discuss favezelimab in metastatic colorectal cancer. The abstract ‘A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer (NCT02720068)’ (abstract number 3584) was presented at the 2021 ASCO […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!